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ABSTRACT 1 
Background: The benefits of routine invasive management in patients with prior coronary 2 
artery bypass grafts (CABG) presenting with non-ST elevation acute coronary syndromes 3 
(NSTE-ACS) are uncertain because these patients were excluded from pivotal trials. 4 
Methods: In a multicenter trial, NSTE-ACS patients with prior CABG were prospectively 5 
screened in 4 acute hospitals. Medically stabilized patients were randomized to invasive 6 
management (Invasive Group) or non-invasive management (Medical Group). The primary 7 
outcome was adherence with the randomized strategy by 30-days. A blinded, independent 8 
Clinical Event Committee adjudicated pre-defined composite outcomes for efficacy (all-9 
cause mortality, rehospitalization for refractory ischemia/angina, MI, hospitalization due to 10 
HF) and safety (major bleeding, stroke, procedure-related MI, and worsening renal function). 11 
Results: Two hundred and seventeen patients were screened and 60 (mean±SD age, 71±9 12 
years, 72% male) were randomized (Invasive Group, n=31; Medical Group, n=29). One third 13 
(n=10) of the participants in the Invasive Group initially received PCI. In the Medical Group, 14 
one participant crossed over to invasive management on day 30 but PCI was not performed. 15 
During 2-years’ follow-up (median (IQR) 744 (570-853) days), the composite outcome for 16 
efficacy occurred in 13 (42%) subjects in the Invasive Group and 13 (45%) subjects in the 17 
Medical Group. The composite safety outcome occurred in 8 (26%) subjects in the Invasive 18 
Group and 9 (31%) subjects in the Medical Group. An efficacy or safety outcome occurred in 19 
17 (55%) subjects in the Invasive Group and 16 (55%) subjects in the Medical Group. Health 20 
status (EQ-5D) and angina class in each group were similar at 12 months. 21 
Conclusions: More than half of the population experienced a serious adverse event. An 22 
initial non-invasive management strategy is feasible. A substantive health outcomes trial of 23 
4 
invasive versus non-invasive management in NSTE-ACS patients with prior CABG seems 24 
warranted. 25 
Clinical Trial Registration Information: URL: https://www.clinicaltrials.gov. Unique 26 
identifier: NCT01895751. 27 
 28 
Key Words: coronary artery bypass graft; acute coronary syndrome; myocardial infarction; 29 
coronary angiography; percutaneous coronary intervention; medical therapy; clinical trial 30 
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NON-STANDARD ABBREVIATIONS AND ACRONYMS 31 
BARC = Bleeding Academic Research Consortium 32 
BCIS = British Cardiovascular Intervention Society 33 
CABG = coronary artery bypass graft 34 
CCS = Canadian Cardiovascular Society 35 
CEC = Clinical Event Committee 36 
CHI = community health index 37 
CTCA = CT coronary angiography 38 
ECG = electrocardiography 39 
e-CRF = electronic case report form 40 
EQ-5D-5L = EuroQol 5 Dimensions 5 Levels 41 
EQ-VAS = EuroQol Visual Analogue Scale (EQ-VAS) 42 
ESC = European Society of Cardiology 43 
FRISC II = FRagmin and Fast Revascularisation during InStability in Coronary artery disease 44 
GRACE = Global Registry of Acute Coronary Events 45 
HF = heart failure 46 
HR = hazard ratios 47 
ICTUS = Invasive versus Conservative Treatment in Unstable Coronary Syndromes 48 
IDMC = Independent Data and Safety Monitoring Committee 49 
ISAR-COOL = Intracoronary Stenting with Antithrombotic Regimen Cooling-Off 50 
LAD = left anterior descending 51 
LIMA = left internal mammary graft 52 
LIPSIA-NSTEMI = The Leipzig Immediate versus early and late PercutaneouS coronary 53 
Intervention triAl in NSTEMI 54 
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MACE = major adverse cardiac event 55 
MATE = Medicine versus Angiography in Thrombolytic Exclusion 56 
MI = myocardial infarction 57 
MOSCA = coMOrbilidades en el Síndrome Coronario Agudo 58 
NHS = National Health Service 59 
NIHR = National Institute for Health Research 60 
NSTE-ACS = non-ST elevation acute coronary syndrome 61 
OASIS-5 = Fifth Organization to Assess Strategies in Ischemic Syndromes 62 
PCI = percutaneous coronary intervention 63 
RBH = Royal Blackburn Hospital 64 
RCA = right coronary artery 65 
RITA 3 = Randomized Intervention Trial of unstable Angina 66 
SD = standard deviation 67 
TACTICS-TIMI 18 = Treat Angina with Aggrastat and Determine Cost of Therapy with an 68 
Invasive or Conservative Strategy – Thrombolysis in Myocardial Infarction 18 69 
TIMI IIIB = Thrombolysis in Myocardial Ischemia 70 
TMG = Trial Management Group 71 
TRUCS = Treatment of Refractory Unstable angina in geographically isolated areas without 72 
Cardiac Surgery 73 
VANQWISH = Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital 74 
VINO = Value of first day angiography/angioplasty In evolving Non-ST segment elevation 75 
myocardial infarction: an Open multicenter randomized trial 76 
 77 
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WHAT IS KNOWN; WHAT THE STUDY ADDS 78 
What is Known 79 
• There is an evidence-gap on the safety and efficacy of invasive management in patients 80 
with a prior coronary artery bypass graft (CABG) because they were excluded from 81 
several clinical trials of routine invasive management versus conservative management. 82 
What the Study Adds 83 
• In a randomized, multicenter trial, we obtained 'proof-of-concept' information on 84 
feasibility, efficacy and safety of routine medical management compared with invasive 85 
management in medically stabilized patients following an acute non-ST segment 86 
elevation acute coronary syndrome (NSTE-ACS) and a history of prior CABG. 87 
• Health outcomes and quality of life during a median of over 2 years follow-up were 88 
similar for patients in each group. 89 
• In the Invasive Group, percutaneous coronary intervention (PCI) was performed in one 90 
third of the participants whilst in the Medical Group, only one (3.4%) participant crossed 91 
over to invasive management on day 30 but PCI was not performed. 92 
• A comparative effectiveness trial involving contemporary invasive and medical therapies 93 
seems justified. 94 
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SUMMARY FIGURE 95 
Central Figure. 96 
97 
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INTRODUCTION 98 
Based on the results of 10 randomized trials of invasive versus conservative medical 99 
management in patients with a non-ST segment elevation acute coronary syndrome (NSTE-100 
ACS)1,2 (Table 1)3-18, invasive management is associated with a Class 1 practice guideline 101 
recommendation (Level of Evidence A).19–21 Around 1 in 10 patients admitted to hospital 102 
with an acute NSTE-ACS have a history of prior coronary artery bypass graft surgery 103 
(CABG).19–22 CABG is a standard of care for patients with obstructive coronary artery 104 
disease, however, reflecting the natural history of saphenous vein graft disease, graft 105 
occlusion is common within 10 years of surgery.23–25 Patients with prior CABG have a 106 
progressive longer-term risk of recurrent ischemia, including angina (>6% at 1-year),26 107 
myocardial infarction (MI) (>7% after 6 years,27 or >10% within 10 years),28 hospitalization 108 
for heart failure (HF) (2% within 30 days)29 and death (>2% at 1 year,30,31 rising to >4-9% 109 
after 5 years).22,27,32,33 This group of patients presents a challenge to healthcare providers 110 
globally, not least because of their elderly age and multi-morbidity. 111 
Some of the pivotal trials of invasive versus conservative management in NSTE-ACS, 112 
including TIMI IIIB,7 FRISC II,34 and RITA 3,10 excluded patients with prior CABG (Table 113 
1). Therefore, the relevance of practice guideline recommendations19,20,35 and balance of risks 114 
and benefits in this large sub-group of patients is less certain.36–38 When invasive 115 
management is performed, revascularization with either percutaneous coronary intervention 116 
(PCI) or re-do CABG is less likely in NSTE-ACS patients with prior CABG.37–40 On the 117 
other hand, advances in percutaneous revascularization techniques create new therapeutic 118 
possibilities for this patient group. 119 
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A substantive, health outcome trial of invasive management involving contemporary 120 
techniques versus non-invasive management seems warranted. However, critical 121 
uncertainties relating to the feasibility of enrolment, adherence to the randomized strategy 122 
and overall safety undermine the rationale for such a trial. 123 
In this study, we aimed to assess the feasibility and safety of routine non-invasive versus 124 
invasive management in patients with NSTE-ACS and prior CABG in a multicenter setting. 125 
To address this aim we undertook a randomized, controlled, pilot trial of routine invasive 126 
management (standard of care) versus non-invasive medical management. The primary 127 
hypothesis was that in patients with NSTE-ACS and prior CABG randomization to medical 128 
management is routinely feasible, as reflected by adherence to this strategy by 30 days. 129 
Evidence of efficacy and safety in the longer term was prospectively assessed. The efficacy 130 
of each strategy was assessed by blinded assessment of all-cause mortality, non-fatal MI or 131 
hospitalization for HF events during longer term follow-up. The safety of each strategy was 132 
assessed by comparison of bleeding (Bleeding Academic Research Consortium (BARC) 133 
types 2-4),41 stroke, procedure-related MI (Type 4a, European Society of Cardiology (ESC) 134 
Universal Definition of MI),42 and worsening renal function or hemodialysis events during 135 
the index hospitalization.136 
 METHODS 137 
The data that support the findings of this study are available from the corresponding author 138 
upon reasonable request. 139 
Study design and setting 140 
The design of this pilot trial has been previously described.18 The participants were enrolled 141 
in four acute hospitals in the National Health Service (NHS), U.K., including two large urban 142 
hospitals (Western Infirmary and Royal Infirmary, Glasgow) and two regional hospitals 143 
(Royal Alexandra Hospital, Paisley and Royal Blackburn Hospital (RBH)). More details 144 
about these hospitals are detailed in Supplement. 145 
Population 146 
Eligibility for randomization in the trial was based on the following criteria: 147 
Inclusion: 1) Unstable angina or non-ST segment elevation MI; 2) Stabilized symptoms 148 
without recurrent chest pain or intravenous therapy for 12 hours; 3) Prior CABG. 149 
Exclusion: 1) Refractory ischemia (i.e. recurrent angina with minimal exertion or at rest (i.e. 150 
Canadian Cardiovascular Society (CCS) class III or IV) not controlled by medical therapy); 151 
2) Cardiogenic shock; 3) Lack of informed consent; 4) Unsuitable for invasive management. 152 
Patients who fulfilled the eligibility criteria were provided with an information sheet as soon 153 
as feasible after hospital admission and before referral for coronary angiography. Written 154 
informed consent was required for participation in the trial. 155 
 Screening 156 
The clinical research team on each site screened patients who had been hospitalized during 157 
unscheduled emergency care. Patients who were 18 years and older, of either sex, and who 158 
had a history of NSTE-ACS and prior CABG were prospectively identified. Trial 159 
participation required that the attending physician confirm there was equipoise for the 160 
potential benefits of either invasive management or non-invasive management. If either the 161 
physician or the patient did not agree then the patient was designated as a screen failure. 162 
Informed consent for participation in the follow-up registry was then invited. Each patient 163 
was assigned a unique study number and then entered into a screening log. The community 164 
health index (CHI) or NHS number was recorded to enable electronic record linkage using 165 
routinely collected NHS datasets. 166 
Randomization 167 
Patients who fulfilled the inclusion criteria and did not have any exclusion criteria and who 168 
also had provided written informed consent were enrolled into the trial. Randomization was 169 
performed using an interactive voice recognition system managed by the Glasgow Clinical 170 
Trials Unit. Participants were randomized 1:1 to either the Invasive Group or Medical Group. 171 
Randomization was stratified by center, using randomized permuted blocks of length 4 and 6, 172 
with block lengths chosen at random. 173 
Medical therapy 174 
Optimal medical therapy was recommended for participants in both of the randomized 175 
groups. Guidance on up-titration of medical therapy in both groups was provided in an 176 
investigator guideline. Medical therapy included dual anti-platelet, anti-thrombotic, and anti-177 
anginal therapies as per local protocols and international guidelines.19,20 178 
 Medical Group 179 
According to the trial protocol, study participants who had been randomized to the Medical 180 
Group i.e. non-invasive management, could be referred for invasive management if pre-181 
specified criteria (Supplement) occurred post-randomization: 182 
Invasive Group 183 
Invasive management was performed early (i.e. ≤ 72 hours wherever possible) after hospital 184 
admission. Invasive management included native coronary and bypass graft angiography and 185 
coronary and/or graft revascularization with PCI and/or CABG, as clinically appropriate. 186 
Screen failures  187 
Screened patients who were (1) eligible but did not consent to participate in the randomized 188 
trial or (2) did not meet eligibility criteria (Figure 1. CONSORT diagram); were included in 189 
a screen failure log. 190 
Registry 191 
The reasons for non-participation of patients who were eligible for randomization were 192 
prospectively recorded: physician preference, patient preference, or both (Figure 1. 193 
CONSORT diagram). 194 
Follow-up 195 
Clinical research nurses and physicians who were independent of the study teams and aware 196 
of the group allocations conducted the follow-up assessments. They prospectively gathered 197 
information on screening, recruitment, randomization (to medical therapy or invasive 198 
 management), cross-over rates, and serious adverse events in patients with prior CABG and a 199 
recent NSTE-ACS. 200 
Sample Size 201 
The sample size of 60 randomized participants was predetermined to be sufficient to provide 202 
information on the feasibility of randomization in a consecutive series of patients with NSTE-203 
ACS and prior CABG who had been prospectively enrolled, ad hoc, during unscheduled care. 204 
The sample size was also intended to be sufficient to provide information on adherence with 205 
the allocated strategy within the first 30 days. The trial was not powered to assess for 206 
between-group differences in the rates of the serious adverse events contributing to the 207 
prespecified efficacy and safety outcomes. 208 
Outcomes 209 
Serious adverse events during the index admission and follow-up were detected by contacting 210 
the participants at 6- and 12 months following enrolment, by reviewing medical records 211 
obtained during usual care, and routinely collected electronic health databases, including the 212 
CHI number and NHS number. The occurrence of these outcomes was prospectively entered 213 
into an electronic case report form (e-CRF). 214 
Primary Outcome 215 
The primary outcome was the post-randomization rate of major adverse events (co-primary 216 
composite outcome), including one composite outcome for efficacy and one composite 217 
outcome for safety. The comparison between the incidences of each outcome according to 218 
treatment group assessed the between-group difference in the proportion of major adverse 219 
events in patients allocated to non-invasive conservative management compared to invasive 220 
management. 221 
 Primary Efficacy Outcome 222 
Defined as all-cause mortality, rehospitalization for refractory ischemia/angina, MI, or 223 
hospitalization for HF. The endpoints were assessed during the study until the final 224 
randomized patient had completed 18 months follow-up. 225 
Primary Safety Outcome 226 
Defined as bleeding (Bleeding Academic Research Consortium (BARC) types 2-4),41 stroke, 227 
procedure-related MI (Type 4a, ESC Universal Definition of MI),42 worsening renal function 228 
or hemodialysis during the index hospitalization. 229 
Secondary Outcomes 230 
1) Quality of life 231 
EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ-VAS) 232 
were assessed at baseline and 6 monthly intervals for a minimum of 18 months. 233 
2) CCS angina class 234 
3) Hospitalization for refractory ischemia 235 
The definition of refractory ischemia is detailed in Supplement. 236 
4) Invasive management during follow-up 237 
5) Coronary and/or bypass graft intervention during follow-up 238 
Clinical Event Committee 239 
An independent Clinical Event Committee (CEC) reviewed serious adverse events that 240 
potentially fulfilled the definition of a primary outcome event. The CEC was blinded to all 241 
information relating to the randomization group. The CEC reviewed cases of interest to 242 
 determine if they met the criteria defined in the pre-specified charter.  Causality assessments 243 
were not made by the CEC. The CEC included 4 cardiovascular physicians with expertise in 244 
the diagnosis and treatment of cardiovascular disorders and in the medical aspects of clinical 245 
trials. The CEC included a Chair (MCP) and a coordinator (MMYL) to assist with 246 
preparation of de-identified source clinical data, reports and communication with the clinical 247 
trials unit. The CEC followed a pre-determined adjudication charter. 248 
Definitions of adverse events 249 
The adverse events of death, procedure-related MI, stroke, major bleeding and worsening 250 
renal function are defined as detailed in Supplement. 251 
Follow-up and timing of outcome evaluations 252 
Follow-up (via telephone contact, clinic visits, letter) with completion of quality of life 253 
assessments (EQ-5D-5L and EQ-VAS) was maintained at 6 monthly intervals until a 254 
minimum of 18 months follow-up had been reached for the final recruited patient. Consent 255 
was obtained for long-term follow-up analyses. 256 
Following randomization, clinical assessments involved gathering information from the 257 
standard-of-care clinical reviews (end of hospitalization, 30-42 days and 1 year) and also 258 
from clinical contacts recorded in the patients’ medical records. In West of Scotland 259 
hospitals, a single system of electronic patient records is used for all hospital attendances and 260 
correspondence with primary care. 261 
Cross-over 262 
A cross-over from one randomized group to another was pre-defined as a change of treatment 263 
strategy from invasive to non-invasive management or vice versa within 30 days of 264 
randomization. While the intention-to-treat in each group was either with non-invasive or 265 
 invasive management, all treatment options remained available according to patient and 266 
physician preference i.e. patients initially randomized to medical therapy could have 267 
undergone invasive management and vice versa. No additional interventions were proposed 268 
nor were procedures withdrawn that would be needed on clinical grounds. 269 
Data management and biostatistics 270 
The Robertson Centre for Biostatistics acted as an independent coordinating center for 271 
randomization, data management and statistical analyses. The Centre is part of the registered 272 
Glasgow Clinical Trials Unit (National Institute for Health Research (NIHR) Registration 273 
number: 16). The Chief Investigator (CB) had full access to all the data in the study and takes 274 
responsibility for its integrity and the data analysis 275 
Statistical analysis 276 
Baseline characteristics of the randomized participants were summarized by group using 277 
mean (standard deviation (SD), or median (lower quartile, upper quartile for skewed data) for 278 
continuous variables and count (%) for categorical variables. Numbers of events and numbers 279 
of patients with events were summarized. Time to occurrence of the primary efficacy and 280 
safety outcomes was summarized using Kaplan-Meier survival curves. Cox models were 281 
fitted to the time to primary efficacy outcome, primary safety outcome, both primary efficacy 282 
and safety outcomes and either primary efficacy or safety outcome and the differences 283 
between the Invasive and Medical Groups presented as hazard ratios (HR) and corresponding 284 
95% confidence intervals. Descriptive statistics only were produced for the secondary 285 
outcomes, due to the study being a pilot trial and not adequately powered for hypothesis 286 
testing for these outcomes. 287 
 Ethics 288 
The research study was reviewed and approved by the West of Scotland NHS Research 289 
Ethics Service (Reference 11-WS-0116). 290 
Trial management 291 
A Trial Management Group (TMG) including the researchers and Local Principal 292 
Investigator on each of the 4 sites coordinated the study’s activities on a day-to-day basis. 293 
The NHS Sponsor monitored the trial. Since the trial was a pilot, there was no Independent 294 
Data and Safety Monitoring Committee (IDMC). The ClinicalTrials.gov registration was 295 
NCT01895751.43296 
 RESULTS 297 
Two hundred and seventeen patients with an unplanned hospitalization for a confirmed or 298 
suspected NSTE-ACS and a history of prior CABG were screened during a 16-month period. 299 
The first patient was enrolled on February 20, 2012 (Figure 1. CONSORT diagram). Eighty-300 
four (39%) of these patients were screen failures, including 24 (29%) who did not give 301 
consent and 60 (71%) who were ineligible (≥1 reason). The reasons for being ineligible 302 
included: lack of a confirmed NSTE-ACS (n=42 (70%) patient), persisting unstable 303 
symptoms (n=39 (65%) patients), refractory ischemia (n=5 (8%) patients), unsuitable for 304 
invasive management (n=22 (37%) patients), no prior CABG (n=4 (7%) patients), and unable 305 
to provide informed consent (n=3 (5%) patients). 306 
One hundred and thirty-three (61%) subjects fulfilled eligibility criteria for the randomized 307 
trial (Figure 1) and 60 (mean±SD 71±9 years of age, 43 (72%) male) were enrolled into the 308 
trial and randomized. Seventy-three (mean±SD 72±10 years of age, 53 (73%) male) patients 309 
who were eligible for the trial were not randomized because of physician-preference (n=58), 310 
patient-preference (n=28), or both (n=15). The mean ages of the patients in the registry 311 
(72±10 years) and trial groups (71±9 years) were similar (p=0.46), as were the proportions of 312 
women (20 (27%) vs. 17 (28%); p=1.00). 313 
Baseline characteristics 314 
The characteristics of the trial participants are described in Table 2 and a clinical case is 315 
illustrated in Figure 2. The mean age was 71 years, and all of the participants had at least one 316 
concomitant health problem. Multi-morbidity was very common (Table 2). Two thirds had a 317 
history of hypertension, one third had diabetes, one quarter had heart failure and one fifth had 318 
 cerebrovascular disease or renal failure. The sample averages and rates of other co-319 
morbidities, age, sex, Charlson Comorbidity Index, CCS grade, frailty score and medications 320 
were broadly similar between the groups. Fifty (83%) of the trial participants had a history of 321 
a left internal mammary artery graft. 322 
Medical therapy 323 
Changes in secondary preventive medications and anti-anginal therapy during the index 324 
hospitalization were prescribed in the majority of participants and the changes in medical 325 
therapy were similar in each group (Table 3). 326 
Invasive management 327 
Invasive management was performed in all 31 participants in the Invasive Group (Table 4). 328 
PCI was performed in 10 (32%) participants in the Invasive Group during the index 329 
hospitalization and four more patients in this group received PCI during a second procedure 330 
as part of a staged management plan (n=14 (45%), overall). The mean British Cardiovascular 331 
Intervention Society (BCIS)-1 Jeopardy Score at baseline in the Invasive Group pre- and 332 
post-PCI was 4.3±3.7 and 2.4±2.5 respectively, out of a possible maximum score of 12 333 
(Table 4). During follow-up (≥18 months), 39 coronary angiogram procedures were 334 
performed in the Invasive Group (including 17 (44%) proceeding to PCI). 335 
In the Medical Group, one male patient crossed-over to invasive management on day 30 post-336 
randomization because of recurrent angina. No revascularization targets were identified by 337 
coronary and graft angiography and medical management was adopted. Fifteen (52%) 338 
participants assigned to the Medical Group had an invasive procedure during the follow-up 339 
period and 7 (47%) of these patients received PCI. Overall, 18 invasive procedures were 340 
 performed in this group and 7 (24%) patients were treated with PCI. None of the randomized 341 
patients received redo-CABG. 342 
Health outcomes 343 
During approximately 2-years’ follow-up (median (interquartile range) 744 (570-853) days), 344 
the composite efficacy outcome of all-cause mortality, non-fatal MI, refractory ischemia or 345 
HF hospitalization occurred in 13 (42%) participants in the Invasive Group and in 13 (45%) 346 
in the Medical Group (HR (95% CI) 0.85 (0.39, 1.83) (Table 5). Five participants died in the 347 
Invasive Group (2 cardiovascular, 2 non-cardiovascular and 1 unknown cause) and 3 died in 348 
the Medical Group (2 non-cardiovascular and 1 unknown cause). 349 
The composite safety outcome of major bleeding (BARC types 2-4), stroke, procedure-350 
related MI, or worsening renal function occurred in 8 (26%) participants in the Invasive 351 
Group and in 9 (31%) participants in the Medical Group (HR (95% CI) 0.87 (0.34, 2.25)) 352 
(Table 5). Bleeding occurred in 4 (13%) and 7 (24%) patients in the Invasive and Medical 353 
Groups, respectively. Worsening renal function occurred in 5 patients in the Invasive Group 354 
compared to 3 patients in the Medical Group. 355 
Overall, 33 (55%) participants experienced at least one of these events: 17 (55%) of 31 356 
participants in the Invasive Group and 16 (55%) of participants in the Medical Group (HR 357 
(95% CI): 0.96 (0.48, 1.90). The Kaplan-Meier survival curves are shown in Figure 3. 358 
Overall, there were no differences between the groups. The time-course for efficacy events 359 
appeared to differ between the groups with proportionately more events occurring earlier in 360 
the Medical Group and proportionately more events occurring later in the Invasive Group. 361 
 Health status 362 
Compared to the Medical Group, the Invasive Group had higher degree of impairment in 363 
health-related quality of life (e.g. lower EQ-5D-5L score) at baseline (Table 2) and 6 months, 364 
but by 12 months the average group scores were similar (Table 5). 365 
Angina 366 
Functional limitation from angina, reflected by the CCS angina class, was similar between 367 
the groups at 6 and 12 months. 368 
 DISCUSSION 369 
This study informs the evidence-gap relating to invasive versus medical management in 370 
patients presenting with an acute NSTE-ACS and prior CABG. We report the first 371 
randomized, controlled, multicenter, trial of invasive and non-invasive management 372 
strategies in this patient group. The main findings are 1) enrolment into the randomized trial 373 
was feasible but challenging (Figure 1. CONSORT diagram). The age and sex distributions 374 
of the patients in the trial and registry groups were similar, suggesting minimal selection bias; 375 
2) adherence to the randomized strategy within the 30 day cross-over period was achieved in 376 
all but one of the participants; 3) revascularization was initially performed in only one third 377 
of the Invasive Group; 4) the majority of the trial population experienced a major adverse 378 
event during follow-up; and 5) no between-group differences in these events, but the trial was 379 
not powered for these. The trial provides proof-of-concept evidence that an initial non-380 
invasive management strategy in NSTE-ACS patients with prior CABG is feasible. 381 
Importantly, the results support the rationale for a substantive health outcome trial of these 382 
strategies in this patient group. 383 
Patients with a prior CABG who present with an acute coronary syndrome have usually 384 
experienced chronic myocardial ischemia for years. In this study, 68% of participants had a 385 
prior MI. The cause of an NSTE-ACS in patients with a prior CABG may be the eventual 386 
occlusion of a chronically diseased graft, a mismatch in myocardial blood supply:demand 387 
(Type 2 MI) whereby collateral blood supply fails to meet myocardial demand, or occlusion 388 
of a native coronary artery. The clinical case presented in our study (Figure 2) is one 389 
example. Chronic ischemia stimulates arteriogenesis promoting coronary collateral 390 
connections to deliver oxygenated blood to ischemic myocardium.44 These micro-391 
connections may be extensive and imperceptible at angiography. 392 
 In our study, a culprit vessel was only identified by the attending cardiologist in half of the 393 
invasively managed patients. This conundrum reflects the diagnostic uncertainties associated 394 
with complex, multivessel native coronary and bypass graft disease. PCI was initially 395 
performed in one third of the Invasive Group. This may reflect uncertainties about 396 
performing complex PCI when the culprit lesion is not obvious and when procedural risks 397 
may be felt to be high. Further, multi-morbidity may limit the potential for revascularization 398 
to improve quality of life. Finally, the overall risk:benefit ratio of performing PCI in this 399 
population may also be influenced by the fact that the participants had stabilized with 400 
medical therapy. PCI was only performed in a minority of the Invasive Group. 401 
Burden of disease 402 
In contemporary trials involving NSTE-ACS patients, the 12-month major adverse cardiac 403 
event (MACE) rate is usually 8 – 10%. In our trial, the rate was over 4-times higher (45% 404 
met either primary efficacy or safety outcomes at 12 months), increasing to 55% overall. The 405 
rising event-rate over time contrasts with other trials in NSTE-ACS populations in which 406 
MACE rates tend to plateau during the first 3 months post-MI. The older age and universal 407 
presence of multi-morbidity probably explain the differences in prognosis between NSTE-408 
ACS patients with versus without prior CABG. Our results support the hypothesis that 409 
routine non-invasive management could be initially adopted for patients with an NSTE-ACS 410 
and prior CABG except in the minority with ongoing ischemia. 411 
Advances in interventional management 412 
In recent years, radial artery access has become the standard approach for invasive 413 
management rather than femoral artery access. The left radial artery allows access in patients 414 
with a left internal mammary artery graft. Adoption of advanced techniques for 415 
revascularization of chronic native vessel occlusive disease might lead to higher rates of 416 
 successful revascularization.45 This possibility could be prospectively assessed in a larger 417 
multicenter trial. 418 
Non-invasive imaging 419 
Functional imaging to elicit inducible ischemia, notably with stress cardiovascular magnetic 420 
resonance, echocardiography or myocardial perfusion scintigraphy, may be useful. However, 421 
these tests may be logistically challenging to perform on an emergent basis. CT coronary 422 
angiography (CTCA) is useful for imaging grafts but not necessarily for imaging native 423 
coronary arteries since calcification provokes artefacts, reducing diagnostic accuracy. For this 424 
reason, in our opinion, CTCA has limited clinical utility to provide a comprehensive 425 
diagnostic evaluation in this patient population. 426 
Future substantive trial of invasive versus non-invasive management in patients with a 427 
NSTE-ACS and prior CABG 428 
Some of the previous pivotal trials excluded patients with prior CABG (Table 1). The 429 
reasons for excluding these patients may be because of their distinct complexities relating to 430 
occlusive native vessel coronary artery disease, graft disease and concomitant health 431 
problems. Consequently, practice guidelines are not evidence-based in this sub-group 432 
meaning that clinicians lack relevant information to inform decision-making. 433 
One of the primary aims of our pilot trial was to provide information on whether a larger trial 434 
in this NSTE-ACS sub-group might be feasible. Adherence to the randomized strategy was 435 
achieved in all but one of the participants, indicating that the interventions were feasible. Half 436 
of the Medical Group subjects underwent invasive angiography during follow-up but only a 437 
minority (24%) received PCI. 438 
 This study was logistically challenging to deliver. Firstly, the grant committee raised concern 439 
about the ethics of randomizing study participants to non-invasive management and rejected 440 
our application for funding. The results of our trial provide reassurance in this regard. 441 
Without core funding support, this study was all the more difficult to deliver. Screening and 442 
enrolment were time-consuming. The population mainly included frail and elderly 443 
participants (mean age 71±9 years) (Table 2). Physician preference was a determining factor 444 
for enrolment. Over half of the patients screened were deemed ineligible for randomization 445 
based on physician preference. Our experience indicates that a multicenter phase 3 trial will 446 
present logistical challenges. To deliver that trial, support from physicians during urgent care 447 
will be needed. To that end, we hope that the preliminary evidence of similar adverse event 448 
rates between the groups will give physicians and patients confidence to participate. We 449 
envisage the future trial would be pragmatic, with an all-comers approach to enrolment and 450 
eligibility criteria similar to the pilot. We envisage a non-inferiority design for invasive vs. 451 
non-invasive management and a primary composite outcome that includes all-cause mortality 452 
and spontaneous adverse events that are not determined by clinicians’ decisions to minimize 453 
bias. The trial will champion advanced interventional techniques for native vessel 454 
revascularization. If the non-inferiority hypothesis is confirmed then non-invasive 455 
management could be considered a default standard of care for medically stabilized patients. 456 
Potential impact of a future trial 457 
About 1 in 10 NSTE-ACS patients have prior CABG. This rate is likely to remain stable in 458 
the coming years reflecting sustained referrals for CABG in the past decade and increasing 459 
longevity. Our results support the hypothesis that a non-invasive strategy could be initially 460 
adopted for most NSTE-ACS patients with prior CABG, reserving invasive management for 461 
patients with persistent or recurrent, ischemia. The results from a future phase 3/4 trial could 462 
 be implemented in daily practice, potentially reducing variations in management, enabling 463 
more efficient resource utilization, and allowing NSTE-ACS patients with prior CABG to 464 
reach critical points in the care pathway more quickly. 465 
Limitations 466 
The sample size is insufficient to draw conclusions about the effectiveness of the clinical 467 
strategies. The study pre-dates recent advances in interventional techniques for chronic 468 
occlusive coronary artery disease. 469 
Conclusion  470 
In a pilot study, we observed no difference in clinical outcomes between patients with NSTE-471 
ACS and prior CABG undergoing either non-invasive or routine invasive management. A 472 
randomized trial of these strategies is feasible. A substantive trial involving contemporary 473 
invasive and medical therapies seems warranted.474 
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 FIGURE LEGENDS 699 
Central Figure. 700 
Figure 1. CONSORT flow diagram. 701 
Figure 2. Clinical case. 702 
A 51-year-old male was hospitalized following an acute non-ST elevation acute coronary 703 
syndrome (NSTE-ACS). (A) 12-lead electrocardiography (ECG) demonstrated atrial 704 
fibrillation with ST depression and T wave inversion in the lateral leads, which were not 705 
significantly changed from previous ECGs. The Global Registry of Acute Coronary Events 706 
(GRACE) score for death or MI within 6 months was 107. The past medical history included 707 
coronary artery bypass grafting fourteen years previously, left ventricular systolic 708 
dysfunction, a cardiac defibrillator for primary prevention, and atrial fibrillation. The surgical 709 
record and graft history were not available. The day after admission to hospital, the patient 710 
provided written informed consent to participate in the CABG-ACS trial. He was randomized 711 
to the Invasive Group. Coronary angiography was performed on an urgent basis via the left 712 
radial artery. (B) The native left main coronary artery was occluded at the ostium (white 713 
arrow). (C) The saphenous vein grafts to the right coronary artery (RCA) (red arrow) and 714 
obtuse marginal branch of the left coronary artery (orange arrow) were also occluded. (D) 715 
Angiography of the native RCA revealed proximal and mid-vessel occlusions associated with 716 
bridging ipsilateral collateral connections (green arrow). (E) The left internal mammary 717 
artery (LIMA) graft had a 70-80% stenosis (dark red arrow) involving the anastomosis with 718 
the left anterior descending (LAD) coronary artery with normal antegrade flow. This lesion 719 
was judged to be the culprit. The LIMA supplied collaterals to the distal branches of the RCA 720 
pointing to a large territory of jeopardized myocardium. Given the history of left ventricular 721 
 dysfunction, the ischemic area-at-risk, and risks of percutaneous coronary intervention (PCI) 722 
to this stenosis, the treatment plan was for deferred management including up-titration of 723 
anti-angina drug therapy and PCI to the LIMA should symptoms became refractory. (F) Two 724 
months later, the patient was readmitted because of persistent angina, and PCI to the 725 
insertional stenosis of the LIMA-LAD anastomosis stenosis was then performed (yellow 726 
arrow). Following pre-dilatation, a 3.0 x 28 mm drug eluting stent was deployed at 17 727 
atmospheres. PCI was completed with high inflation post-dilatation and an excellent final 728 
result was obtained. (G) Angiography at the end of the procedure revealed antegrade filling 729 
of the distal LAD and retrograde filling of the posterior descending branch of the RCA via 730 
collateral connections from the LIMA-LAD system (light green arrow). Dual antiplatelet 731 
therapy was prescribed for 12 months. The patient was hospitalized on 3 further occasions. 732 
He experienced a Type 1 NSTEMI four months later. In-stent restenosis was diagnosed and 733 
treated with additional PCI. Two months later he was then hospitalized with unstable angina 734 
and two months after that he experienced another Type 1 NSTEMI. He was medically 735 
managed on these occasions. 736 
Figure 3. Kaplan-Meier survival curves for time to occurrence of the composite 737 
outcomes for efficacy and safety, by study group. 738 
 TABLES 739 
Table 1. Trials of patients with non-ST elevation acute coronary syndromes 740 
Trials which included patients with prior CABG 
Trial Year published N N (%) with prior CABG 
     VANQWISH3 1998 920 156 (17.0%)* 
     MATE4 1998 201   19 (9.5%) 
     TRUCS11 2000 148 18 (12.2%) 
     TACTICS-TIMI 1812 2001 2220 484 (21.8%)† 
     ISAR-COOL13 2003 410 48 (11.7%) 
     ICTUS14 2005 1200 105 (8.8%) 
     OASIS-515 2009 20078 1643 (8.2%) 
     LIPSIA-NSTEMI16 2012 600 41 (6.8%) 
     Italian Elderly ACS17 2012 313 29 (9.3%) 
     CABG-ACS pilot18 2013 60 60 (100.0%) 
     After Eighty Study5 2016 457 76 (16.6%) 
     MOSCA6 2016 106 14 (13.2%) 
Trials which excluded patients with prior CABG 
Trial Year published N Exclusion 
     TIMI IIIB7 1994 1473 CABG at any time 
     FRISC II8 1999 2457 Previous open-heart surgery 
     VINO9 2002 131 CABG less than 6 months 
     RITA 310 2002 1810 CABG at any time 
  741 
Footnote: * CABG > 3 months before randomization. † CABG >6 months before randomization. 742 
 Table 2. Baseline clinical and angiographic characteristics of the trial participants 743 
Characteristic All 
(N = 60) 
Invasive 
(N = 31) 
Medical 
(N = 29) 
Age (years)* 71±9 69±10 73±8 
Female 17 (28%) 7 (23%) 10 (34%) 
Obesity (BMI >30 kg/m2) 22 (37%) 12 (39%) 10 (34%) 
NSTEMI 41 (68%) 21 (68%) 20 (69%) 
Unstable angina 19 (32%) 10 (32%) 9 (31%) 
Diabetes mellitus† 21 (35%) 10 (32%) 11 (38%) 
Previous myocardial infarction 41 (68%) 23 (74%) 18 (62%) 
Cardiac arrhythmia 19 (32%) 12 (39%) 7 (24%) 
Hypertension history 42 (70%) 23 (74%) 19 (66%) 
Peripheral vascular disease 16 (27%) 11 (35%) 5 (17%) 
Cerebrovascular disease 13 (22%) 7 (23%) 6 (21%) 
Congestive cardiac failure 14 (23%) 9 (29%) 5 (17%) 
Renal impairment history 13 (22%) 9 (29%) 4 (14%) 
Creatinine concentration‡ 84 [68-101] 91 [70-107] 83 [67-95] 
Chronic anemia 5 (8%) 3 (10%) 2 (7%) 
Hemoglobin (g/L)* 135±16 136±17 135±16 
Valve disease 12 (20%) 5 (16%) 7 (24%) 
Pacemaker 5 (8%) 3 (10%) 2 (7%) 
Smoking history:    
     current 12 (20%) 7 (23%) 5 (17%) 
     ex (stopped >3 months) 33 (55%) 20 (65%) 13 (45%) 
      never 15 (25%) 4 (13%) 11 (38%) 
Charlson co-morbidity index‡ 4 [3-6] 4 [3-8] 4 [3-5] 
ST-segment depression 28 (47%) 14 (45%) 14 (48%) 
ST-segment elevation 11 (18%) 8 (26%) 3 (10%) 
T-wave inversion 38 (63%) 20 (65%) 18 (62%) 
Q-waves 15 (25%) 9 (29%) 6 (21%) 
Left bundle branch block 5 (8%) 3 (10%) 2 (7%) 
Right bundle branch block 3 (5%) 1 (3%) 2 (7%) 
Atrial fibrillation or flutter 9 (15%) 5 (16%) 4 (14%) 
New ischemic ECG changes§ 30 (50%) 19 (61%) 11 (38%) 
CCS angina class:||    
     I 2 (3%) 0 (0%) 2 (7%) 
     II 6 (10%) 4 (13%) 2 (7%) 
     III 10 (17%) 4 (13%) 6 (21%) 
     IV 41 (69%) 22 (73%) 19 (66%) 
Left internal mammary artery graft 50 (83%) 27 (87%) 23 (79%) 
Saphenous vein graft:    
     0 3 (5%) 2 (6%) 1 (14%) 
     1 17 (29%) 6 (19%) 11 (41%) 
     2 25 (43%) 16 (52%) 9 (33%) 
     ≥3 13 (22%) 7 (23%) 6 (22%) 
Frailty score:    
     Fit or well (1,2,3) 35 (58%) 15 (48%) 20 (69%) 
     Vulnerable (4) or mildly frail  
(5) 
14 (23%) 9 (29%) 5 (17%) 
      Moderately frail (6) 10 (17%) 6 (19%) 4 (14%) 
     Severely frail (7) 1 (2%) 1 (3%) 0 (0%) 
Health-related quality of life, EQ-
5D-5L score 
0.748  
[0.514-0.899] 
0.602  
[0.360-0.881] 
0.863  
[0.596-0.924] 
Medical therapy:    
     Aspirin 52 (87%) 29 (94%) 23 (79%) 
     Statin 55 (92%) 29 (94%) 26 (90%) 
     Beta-blocker 42 (70%) 21 (68%) 21 (72%) 
     Calcium channel blocker 60 (100%) 31 (100%) 29 (100%) 
     Isosorbide mononitrate 20 (33%) 12 (39%) 8 (28%) 
     Nicorandil 22 (37%) 15 (48%) 7 (24%) 
     ACE-inhibitor 50 (83%) 27 (87%) 23 (79%) 
     Insulin 10 (17%) 6 (19%) 4 (14%) 
     Oral anti-diabetic therapy 10 (17%) 5 (16%) 5 (17%) 
     Anti-depressant therapy 13 (22%) 8 (26%) 5 (17%) 
     Diuretic 18 (30%) 8 (26%) 10 (34%) 
     Polypharmacy (≥4 medicines) 57 (95%) 30 (97%) 27 (93%) 
 
Footnote: * Mean±standard deviation. † Diabetes mellitus was defined as a history of diet-
controlled or treated diabetes. ‡ Median [interquartile range]. § Any previous episodes with new 
ischemic ECG changes. || The highest CCS value of any previous episode for each patient. 
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; CCS, Canadian 
Cardiovascular Society; ECG, electrocardiogram; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; 
NSTEMI, non-ST segment elevation myocardial infarction. 
 Table 3. Reasons for changing medical therapy during the index hospitalization 744 
Reason All 
(N = 60) 
Invasive 
(N = 31) 
Medical 
(N = 29) 
Recurrent angina 13 (22%) 9 (29%) 4 (14%) 
Standard optimization of secondary 
preventive therapy 
54 (90%) 26 (84%) 28 (97%) 
Standard optimization of anti-anginal 
therapy 
54 (90%) 29 (94%) 25 (86%) 
Intolerant of medication without adverse 
reaction 
2 (3%) 1 (3%) 1 (3%) 
Side effect/adverse reaction 2 (3%) 1 (3%) 1 (3%) 
Other 3 (5%) 1 (3%) 2 (7%) 
 Table 4. Invasive procedures at baseline (index admission) and follow-up (≥18 months) 745 
Subjects with procedures at baseline and follow-up Invasive 
(N = 31) 
Medical 
(N = 15) 
     Subjects with 1 procedure 25 (81%) 12 (80%) 
     Subjects with 2 procedures 5 (16%) 3 (20%) 
     Subjects with 3 procedures 0 (0%) 0 (0%) 
     Subjects with 4 procedures 1 (3%) 0 (0%) 
     Subjects with PCI at baseline 10 (32%) 0 (0.0%) 
     Subjects with PCI at baseline and follow-up 14 (45%) 7 (47%) 
Days from randomization to subject’s first procedure* 13 [4-24] 86 [58-191] 
     < 30 days 25 (81%) 0 (0%) 
     30-59 days 4 (13%) 5 (33%) 
     ≥60 days 2 (6%) 10 (67%) 
Procedures at baseline 
Invasive 
(N = 31) 
Medical 
(N = 0) 
     BCIS-1 Jeopardy Score (pre-PCI) at baseline† 4.3±3.7 - 
     PCI at baseline 10 (32%) - 
     BCIS-1 Jeopardy Score (post-PCI) at baseline† 2.4±2.5 - 
Procedures at baseline and follow-up 
Invasive 
(N = 39) 
Medical 
(N = 18) 
     Urgent in-patient procedure 16 (41%) 11 (61%) 
     Outpatient procedure 23 (59%) 7 (39%) 
     Hospitalization‡ 17 (44%) 11 (61%) 
     Complications related to angiogram§ 1 (3%) 0 (0%) 
     Culprit vessel unknown 18 (46%) 9 (50%) 
      Culprit vessel identified 21 (54%) 9 (50%) 
          Graft only 12 (57%) 5 (56%) 
          Native artery only 9 (43%) 3 (33%) 
          Both graft and native artery 0 (0%) 1 (11%) 
          Multiple culprit lesions 2 (10%) 1 (11%) 
     PCI at baseline and follow-up 17 (44%) 7 (39%) 
          Thrombus aspiration 0 (0%) 1 (14%) 
          Rotational atherectomy 3 (18%) 1 (14%) 
          Intravascular ultrasound 2 (12%) 0 (0%) 
          Distal protection device 2 (12%) 1 (14%) 
 
Footnote: * Median [interquartile range]. † Mean±standard deviation. ‡ ≥1 overnight stay. § 
Complication in Invasive Group (n=1) was worsening renal function post-angiography. 
Abbreviations: BCIS, British Cardiovascular Intervention Society; PCI, percutaneous coronary 
intervention. 
 Table 5. Primary and secondary outcomes over follow-up period (≥18 months; median 744 (interquartile range 570-853) days) 746 
Outcomes All 
(N = 60) 
Invasive 
(N = 31) 
Medical 
(N = 29) 
Hazard ratio 
(95% CI) 
Efficacy outcome     
All-cause mortality, rehospitalization for refractory ischemia/angina, MI, 
or hospitalization for heart failure 
26 (43%) 13 (42%) 13 (45%) 0.85 (0.39, 1.83) 
Safety outcome     
Bleeding (BARC types 2-4),41 stroke, procedure-related Type 4 MI, 
worsening renal function or hemodialysis during the index hospitalization 
17 (28%) 8 (26%) 9 (31%) 0.87 (0.34, 2.25) 
Efficacy and safety outcomes (both)  10 (17%) 4 (13%) 6 (21%) 0.62 (0.17, 2.19) 
Efficacy or safety outcomes (either) 33 (55%) 17 (55%) 16 (55%) 0.96 (0.48, 1.90) 
Components of the efficacy and safety outcomes     
     Death  8 (13%) 5 (16%) 3 (10%)  
          Cardiovascular*  2 (3%) 2 (6%) 0 (0%)  
          Non-cardiovascular† 4 (7%) 2 (6%) 2 (7%)  
          Unknown cause 2 (3%) 1 (3%) 1 (3%)  
      Refractory ischemia 0 (0%) 0 (0%) 0 (0%)  
     Non-fatal MI‡ 22 (37%) 9 (29%) 13 (45%)  
     Heart failure 7 (12%) 4 (13%) 3 (10%)  
     Primary efficacy outcome at 12 months  20 (33%) 10 (32%) 10 (34%)  
     Death at 12 months 5 (8%) 4 (13%) 1 (3%)  
     Bleeding (BARC Types 2-4) 11 (18%) 4 (13%) 7 (24%)  
     Stroke 0 (0%) 0 (0%) 0 (0%)  
     Procedure-related MI 0 (0%) 0 (0%) 0 (0%)  
     Worsening renal function 8 (13%) 5 (16%) 3 (10%)  
     Primary safety outcome at 12 months 12 (20%) 7 (23%) 5 (17%)  
Secondary outcomes     
Number of patients with serious adverse event 40 (67%) 20 (65%) 20 (69%)  
Number of serious adverse events per patient§ 1 [0-2] 1 [0-3] 1 [0-2]  
Number of patients with a rehospitalization (any reason) 39 (65%) 20 (65%) 19 (66%)  
EQ-VAS health status 6 months§ 75 [60-80] 80 [40-80] 75 [60-80]  
EQ-5D-5L score 6 months§ 0.82 [0.53-0.94] 0.67 [0.34-0.94] 0.89 [0.67-0.95]  
EQ-VAS health status 12 months§ 70 [50-80] 65 [50-80] 70 [50-80]  
 EQ-5D-5L score 12 months§ 0.82 [0.62-0.95] 0.72 [0.56-0.94] 0.83 [0.72-0.95]  
CCS angina class 6 months§ 3.0 [1.0-4.0] 4.0 [1.0-5.0] 2.5 [1.0-3.0]  
CCS angina class 12 months§ 4.0 [3.0-5.0] 4.0 [4.0-5.0] 4.0 [3.0-5.0]  
 
Footnote: * In Invasive Group: n=1 (death due to heart failure), n=1 (death due to subdural hemorrhage). † In Invasive Group: n=1 (death due to multi-
organ failure), n=1 (death due to lung cancer); in Medical Group, n=1 (death due to bladder cancer), n=1 (death due to gastric malignancy). ‡ In Invasive 
Group: n=5 (type 1 NSTEMI), n=3 (type 2 NSTEMI), n=1 (both types 1 and 2 NSTEMI); in Medical Group: n=10 (type 1 NSTEMI), n=2 (both types 1 
and 2 NSTEMI), n=1 (STEMI). § Median [interquartile range]. None of the patients underwent redo coronary artery bypass graft surgery. 
Abbreviations: BARC, Bleeding Academic Research Consortium; CCS, Canadian Cardiovascular Society; EQ-VAS, EuroQol Visual Analogue Scale; 
EQ-5D-5L, EuroQol 5 Dimensions 5 Levels; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction. 
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